Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916119 | 0.95 | SIGMAR1 (0.37) | SIGMAR1L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL11916112 | 0.92 | SIGMAR1 (0.42) | SIGMAR1TSHRGAAMEN1KMT2A | |
| SCHEMBL1106429 | 0.89 | ALDH1A1 (0.36) | SIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL21933626 | 0.89 | SIGMAR1 (0.34) | SIGMAR1 | |
| SCHEMBL21933628 | 0.89 | SIGMAR1 (0.34) | SIGMAR1 | |
| SCHEMBL9611076 | 0.89 | SIGMAR1 (0.34) | SIGMAR1 | |
| SCHEMBL1106484 | 0.89 | ALDH1A1 (0.40) | SIGMAR1L3MBTL3L3MBTL1GAA | |
| SCHEMBL12563384 | 0.88 | L3MBTL3 (0.39) | SIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL1106434 | 0.88 | L3MBTL3 (0.43) | SIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL14155850 | 0.88 | SIGMAR1 (0.51) | SIGMAR1TSHRGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | SHANGHAI ZHEYE BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | SHANGHAI ZHEYE BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220162228-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8329908-B2 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8268812-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fül Kombinatorische Chemie (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2011-03-10 | — | — | US | disclosed |
| US-7820823-B2 | Dual action antibiotics | Morphochem Aktiengesellschaft Fur Kominatorische Chemi (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | SIGMAR1 4233/4885TSHR 2304/4885L3MBTL3 1267/4885 |
| US-20220162228-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, PSMA6, PSMC2 | SIGMAR1 3395/4885TSHR 4163/4885L3MBTL3 4144/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | SIGMAR1 3576/4885TSHR 3168/4885L3MBTL3 4049/4885 |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | SIGMAR1 4072/4885TSHR 4392/4885L3MBTL3 3105/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | SIGMAR1 4233/4885TSHR 2304/4885L3MBTL3 1267/4885 |
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | TYR, MAPT, DDC | SIGMAR1 4128/4885TSHR 4644/4885L3MBTL3 4408/4885 |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | SIGMAR1 4072/4885TSHR 4392/4885L3MBTL3 3105/4885 |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | OXA1L, ANTXR2, AAAS | SIGMAR1 4072/4885TSHR 4392/4885L3MBTL3 3105/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | SIGMAR1 3112/4885TSHR 2114/4885L3MBTL3 4712/4885 |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, PLA2G2E | SIGMAR1 4251/4885TSHR 2653/4885L3MBTL3 4326/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | SIGMAR1 4233/4885TSHR 2304/4885L3MBTL3 1267/4885 |
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | TYR, APC, TP53 | SIGMAR1 4628/4885TSHR 4532/4885L3MBTL3 4285/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | SIGMAR1 3576/4885TSHR 3168/4885L3MBTL3 4049/4885 |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | SLC11A2, MRPL21, MAP2K5 | SIGMAR1 1314/4885TSHR 3089/4885L3MBTL3 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.